FibroBiologics Prices $3 Million Public Offering

FibroBiologics Prices $3 Million Public Offering
FibroBiologics, a clinical-stage biotechnology company focused on developing therapeutics using fibroblasts for chronic disease treatment, has announced the pricing of its public offering. The company will issue 2,272,728 shares of common stock alongside warrants to purchase an equal number of shares at a combined price of $1.32 per share. This represents a significant capital raise for the Houston-based firm, which holds over 270 patents in its portfolio. The warrants feature an exercise price matching the offering price and will become exercisable following stockholder approval, expiring five years after that approval date. The offering is structured as a best efforts arrangement, meaning the underwriters will use reasonable efforts to sell the securities without guaranteeing a minimum amount.